Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 induction study of obefazimod versus placebo in moderate to severe ulcerative colitis
MOH_2023-06-12_012730Phase 3Completed
- Sponsor
- Abivax
- Start
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of obefazimod in autoimmune colitis (3 arms), sponsored by Abivax. Primary endpoint: Clinical remission. Started Apr 2023; status: completed.
02
Drugs
obefazimod
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on MOH_2023-06-12_012730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-06-12_012730.